Myovant Sciences' Fiscal Q4 Loss Widens YOY
07:30 AM EDT, 05/11/2021 (MT Newswires) -- Myovant Sciences (MYOV) on Tuesday reported a fiscal Q4 net loss of $0.89 per share, compared with a year-ago loss of $0.73 per share. Analysts polled by Capital IQ estimated a loss of $1.00 per share.
The company reported revenue for the quarter of $24.6 million, matching the revenue estimated by Capital IQ. The company did not report revenues for the year-ago quarter.
Among highlights for the quarter, Myovant said the European Medicines Agency validated the marketing authorization application for relugolix for advanced prostate cancer in late March.
The company said it expects the US Food and Drug Administration's ruling on the new drug application for relugolix combination tablet for uterine fibroids by June 1. If approved, the US launch is expected in June. Additionally, the company said it remains on track to submit US regulatory filing for endometriosis in the second quarter.
Further, the company said it is expecting the European Commission's decision on marketing authorization application for uterine fibroids by mid-calendar year 2021.
Price: 18.34, Change: -0.63, Percent Change: -3.32